HIGH TIDE INC (HITI) Stock Fundamental Analysis
NASDAQ:HITI - Nasdaq - CA42981E4013 - Common Stock - Currency: USD
Taking everything into account, HITI scores 4 out of 10 in our fundamental rating. HITI was compared to 195 industry peers in the Pharmaceuticals industry. HITI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HITI has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
In the past 5 years HITI always reported negative net income.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HITI has a better Return On Assets (-4.17%) than 76.92% of its industry peers.
HITI has a Return On Equity of -6.91%. This is in the better half of the industry: HITI outperforms 79.49% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.21%, HITI belongs to the top of the industry, outperforming 83.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROIC | 5.21% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 2.22%, HITI is in the better half of the industry, outperforming 77.95% of the companies in the same industry.
Looking at the Gross Margin, with a value of 25.83%, HITI is in line with its industry, outperforming 53.85% of the companies in the same industry.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HITI is destroying value.
The number of shares outstanding for HITI has been increased compared to 1 year ago.
HITI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HITI has an improved debt to assets ratio.
2.2 Solvency
HITI has an Altman-Z score of 3.10. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HITI (3.10) is better than 75.38% of its industry peers.
The Debt to FCF ratio of HITI is 4.52, which is a neutral value as it means it would take HITI, 4.52 years of fcf income to pay off all of its debts.
HITI has a Debt to FCF ratio of 4.52. This is amongst the best in the industry. HITI outperforms 85.13% of its industry peers.
HITI has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.30, HITI perfoms like the industry average, outperforming 41.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.1 |
ROIC/WACC0.61
WACC8.54%
2.3 Liquidity
HITI has a Current Ratio of 1.57. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of HITI (1.57) is worse than 68.21% of its industry peers.
A Quick Ratio of 0.97 indicates that HITI may have some problems paying its short term obligations.
The Quick ratio of HITI (0.97) is worse than 76.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
HITI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1957.14%.
Looking at the last year, HITI shows a quite strong growth in Revenue. The Revenue has grown by 9.22% in the last year.
The Revenue has been growing by 75.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1957.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1233.33%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%10.9%
3.2 Future
The Earnings Per Share is expected to grow by 74.44% on average over the next years. This is a very strong growth
Based on estimates for the next years, HITI will show a quite strong growth in Revenue. The Revenue will grow by 11.55% on average per year.
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.55%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HITI. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 59.34, the valuation of HITI can be described as expensive.
HITI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HITI is cheaper than 68.21% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, HITI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HITI is valued cheaply inside the industry as 88.21% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, HITI is valued cheaper than 84.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.47 | ||
| EV/EBITDA | 8.21 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HITI does not grow enough to justify the current Price/Earnings ratio.
HITI's earnings are expected to grow with 65.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.97%
EPS Next 3Y65.89%
5. Dividend
5.1 Amount
No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.34
+0.03 (+1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.98%
Inst Owner Change0%
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap189.63M
Analysts80
Price Target5.25 (124.36%)
Short Float %5.39%
Short Ratio11.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.69%
Min EPS beat(2)-11.37%
Max EPS beat(2)-8%
EPS beat(4)1
Avg EPS beat(4)-48.88%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)5
Avg EPS beat(8)27.56%
EPS beat(12)9
Avg EPS beat(12)32.7%
EPS beat(16)11
Avg EPS beat(16)20.33%
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.6%
Revenue beat(4)3
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.9%
Revenue beat(8)5
Avg Revenue beat(8)0.38%
Revenue beat(12)9
Avg Revenue beat(12)1.89%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)3.36%
PT rev (3m)9.27%
EPS NQ rev (1m)14.27%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-69.23%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)-3.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.34 | ||
| P/S | 0.47 | ||
| P/FCF | 18.47 | ||
| P/OCF | 10.44 | ||
| P/B | 1.85 | ||
| P/tB | 5.23 | ||
| EV/EBITDA | 8.21 |
EPS(TTM)-0.1
EYN/A
EPS(NY)0.04
Fwd EY1.69%
FCF(TTM)0.13
FCFY5.42%
OCF(TTM)0.22
OCFY9.58%
SpS4.97
BVpS1.27
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROCE | 6.6% | ||
| ROIC | 5.21% | ||
| ROICexc | 6.43% | ||
| ROICexgc | 16.26% | ||
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 2.55% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 1.22 | ||
| Cap/Depr | 47.33% | ||
| Cap/Sales | 1.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 70.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 3.1 |
F-Score5
WACC8.54%
ROIC/WACC0.61
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1957.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1233.33%
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%10.9%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.55%
EBIT growth 1Y37.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.17%
EBIT Next 3Y105.72%
EBIT Next 5Y69.76%
FCF growth 1Y182.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.28%
OCF growth 3YN/A
OCF growth 5YN/A